(Replaces parliament with congressional, paragraph 1) By Nikolaj Skydsgaard COPENHAGEN (Reuters) -Novo Nordisk on Wednesday rejected allegations by a U.S. congressional investigative committee that it has engaged in manoeuvres to increase net prices on life-saving insulin in tandem with competitors on the U.S. market. The report by the House Oversight Committee, the main investigative body of the U.S. House of Representatives, alleged that Novo had raised its insulin drug prices to the detriment of diabetes patients between 2001 and 2019. Referring to Novo, Eli Lilly and Sanofi, which account …